The development of drugs for HIV treatment and HIV pre-exposure prophylaxis (PrEP) has been extraordinarily successful. Safe and well-tolerated fully suppressive antiretroviral therapy (ART) allows people living with HIV to live longer, healthier lives and prevents transmission of HIV to others. Antiretrovirals approved for PrEP can reduce the risk of infection to near zero if taken as prescribed by uninfected persons at risk for HIV and a key component of HIV prevention programs.
